VPB1297 - Fingerprint of novel circulating microRNAs identify patients with stroke-embolic stroke of undetermined source

Tuesday, July 12, 2022

6:30 PM – 7:30 PM

Location: Exhibition

Presentation Format: Virtual

Co-Author(s)

CE

Ceren Eyileten

Senior Researcher
Department of Experimental and Clinical Pharmacology, Medical University of Warsaw, Center for Preclinical Research and Technology CEPT, 02-091 Warsaw, Poland
Warsaw, Mazowieckie, Poland
Zofia Wicik, PhD

Senior Researcher
Department of Experimental and Clinical Pharmacology, Medical University of Warsaw, Center for Preclinical Research and Technology CEPT, 02-091 Warsaw, Poland
Warsaw, Mazowieckie, Poland
JJ

Joanna Jarosz-Popek

PhD candidate
Medical University of Warsaw
Warsaw, Mazowieckie, Poland
AN

Anna Nowak

PhD candidate
Medical University of Warsaw
Warsaw, Mazowieckie, Poland
AS

Andleeb Shahzadi

Assistant Prof
Istanbul Cerrahpasa University
Istanbul, Istanbul, Turkey
DK

Disha Keshwani

Student
1. Department of Experimental and Clinical Pharmacology, Medical University of Warsaw, Center for Preclinical Research and Technology CEPT, 02-091 Warsaw, Poland
Warsaw, Mazowieckie, Poland
TA

Taqwa Adem

Student
Medical University of Warsaw
Warsaw, Mazowieckie, Poland
DM

Dagmara Mirowska-Guzel

Prof
Medical University of Warsaw
Warsaw, Mazowieckie, Poland
GP

Guillaume Pare

Prof
McMaster University
Hamilton, Ontario, Canada
MP

Marek Postula

Prof
Medical University of Warsaw
Warsaw, Mazowieckie, Poland

Presenting Author(s)

Marta Wolska

Centre for Preclinical Research and Technology (CePT), Medical University of Warsaw

Background: Circulating levels of selected miRNAs open up new avenues for the identification of more effective and specific biomarkers to identify and risk-stratify stroke patients.

Aims: Aim is to identify and select specific miRNAs to be used as disease biomarkers to improve both prognosis and prediction.

Methods: 48 patients with embolic stroke of undetermined source (ESUS) were involved in the study. We divided the patient groups based on patients who had a second stroke or TIA and did not have. Total RNA was extracted from plasma and quality was assessed with fluorometric electrophoresis. Microarray analysis by Affymetrix. Statistical analysis: in TAC software and R using Signal information obtained from the TAC output, FDR correction, logistic regression, calculated AUC using ROCp R package. Coexpression analysis to identify genes authentically expressed was performed using Spearman correlation (cutoff=0.9, Rpval=0.05).

Results: MiR-4786, miR-1205, miR-548ar-3p, miR-518e-3p were found the most differentially expressed miRNAs between the groups (patients with one stroke vs multiple strokes). miR-4786 was studied only in patients with acute leukemia. Several studies showed the importance of miR-1205 in cell carcinoma and ovarian cancer progression. Moreover, so far only one study showed the regulation of miR-548ar-3p in breast cancer. Finally only one study showed the alteration of miR-518e-3p in Parkinson's disease patients. Our enrichment analysis showed IL-2 signaling pathway, lipid and lipoprotein metabolism, BDNF signaling pathway, MAPK signaling pathway, Intellectual Disability, Alzheimer's Disease are significantly related to ESUS- patients.

Conclusion(s): Our results identified several novel circulating miRNAs that are down- or up-regulated in ESUS-stroke patients, as showing the predictive significance for the assessment of risk of the second stroke. Among those with the most relevant differential expression, several miRNAs were already identified to play a role in the pathophysiology of neurovascular diseases, paving the way to a new class of smart pathophysiology-based biomarkers in stroke.